Aflibercept biosimilar (CinnaGen)

阿柏西普生物类似药（CinnaGen）

Report date: 2022/03/17 18:23:40

Base Information

Drug NameAflibercept biosimilar (CinnaGen)

Drug Alias NameN/A

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein

Mechanisms of ActionVascular endothelial growth factor A inhibitorsPlacental Growth Factor inhibitors

TargetsVascular endothelial growth factor APlacental Growth Factor

Therapy Area/IndicationsMacular Degeneration

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIran

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesCinnagen

China Registration ClassN/A

Active CompaniesCinnagen

Inactive CompaniesN/A

Active IndicationsMacular Degeneration

Inactive IndicationsN/A

ATC CodeL01XX44S01LA05